Mark Rothera
2017 - PTC Therapeutics
In 2017, Mark Rothera earned a total compensation of $1.1M as Former Chief Commercial Officer at PTC Therapeutics, a 45% decrease compared to previous year.
Compensation breakdown
| Option Awards | $433,077 |
|---|---|
| Salary | $275,406 |
| Stock Awards | $107,808 |
| Other | $273,855 |
| Total | $1,090,146 |
Rothera received $433.1K in option awards, accounting for 40% of the total pay in 2017.
Rothera also received $275.4K in salary, $107.8K in stock awards and $273.9K in other compensation.
Rankings
In 2017, Mark Rothera's compensation ranked 8,576th out of 14,666 executives tracked by ExecPay. In other words, Rothera earned more than 41.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,576 out of 14,666 | 42nd |
Division Manufacturing | 3,258 out of 5,772 | 44th |
Major group Chemicals And Allied Products | 1,089 out of 2,075 | 48th |
Industry group Drugs | 863 out of 1,731 | 50th |
Industry Pharmaceutical Preparations | 674 out of 1,333 | 49th |
Source: SEC filing on April 30, 2018.
Rothera's colleagues
We found six more compensation records of executives who worked with Mark Rothera at PTC Therapeutics in 2017.
2017
Stuart Peltz
PTC Therapeutics
Chief Executive Officer
2017
Marcio Souza
PTC Therapeutics
Chief Operating Officer
2017
Mark Boulding
PTC Therapeutics
Chief Legal Officer
2017
Neil Almstead
PTC Therapeutics
Executive Vice President, Research, Pharmaceutical Operations & Technology
2017
Christine Utter
PTC Therapeutics
Principal Financial Officer and Treasurer
2017
Shane Kovacs
PTC Therapeutics